• 1
    Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009; 16: 234-239.
  • 2
    Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK. State of the Science 60th Anniversary Review: sixty years of advances in cutaneous melanoma epidemiology, diagnosis and treatment, as reported in the journal Cancer. Cancer. 2008; 113: 1728-1743.
  • 3
    Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009; 60: 872-875.
  • 4
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006; 355: 1307-1317.
  • 5
    Thomas JM. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg. 2009; 62: 442-446.
  • 6
    Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007; 25: 1129-1134.
  • 7
    Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN staging biopsy in these patients. Ann Surg Oncol. 2007; 14: 1596-1603.
  • 8
    Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003; 21: 1326-1331.
  • 9
    Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008; 143: 892-899.
  • 10
    Mays M, Martin RCG, Burton A, et al. Should all patients with melanomas between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer. 2009; 116: 1535-1544.
  • 11
    McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004; 86: 212-223.
  • 12
    Sondak VK, Taylor JMG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004; 11: 247-258.
  • 13
    Chagpar RB, Ross MI, Reintgen DS, et al. Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis. J Surg Res. 2007; 143: 164-168.